SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Receptagen Ltd.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TERENCE DALY who wrote (152)8/2/1998 11:23:00 PM
From: Russell J. Gilbert  Read Replies (1) of 203
 
Personally, I don't think GRN will pursue the CO-Q10 treatment for AIDS.RCG has sat on it for too long and the patent will expire in around 8-9 years. I think they will seek approval for the water soluble solution for stroke victims. At the time RCG purchased the AIDS therapy with CO-Q10 they paid apporx $2,000,000 in cask and stock and then it sat going nowhere over these last 5 years.
What will next week hold? Other than my knee surgury on Wednesday (ouch) I suspect we might see a little action with the stock going between .03 and .05/share.
I would very much like to see some heavy buying coming in soon prior to the closing of the merger.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News